Truncating Variants in RFC1 in Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome

Author(s): Riccardo Ronco1,2; Cecilia Perini, MSc3; Riccardo Currò, MD1,2; Natalia Dominik, MSc1; Stefano Facchin, PhD1; Alice Gennari, MSc1; Roberto Simone, PhD1; Skye Stuart, MSc1; Sara Nagy, MD1,4; Elisa Vegezzi, MD1; Baria Quartesan, MD2; Amar El-Saddig, MD3; Timothy Lavin, MD4; Arianna Tucci, MD, PhD1,5; Agnieszka Szymura, BSc1; Luiz Eduardo Novis De Farias, MD1,6; Alexandre Gary, MSc6; Megan Delfeld, MSc5; Priscilla Kandikatla, MSc6; Nifang Niu, MBBS PhD10; Sanjukta Tawde, MSc11; Joseph Shaw, MSc11; James Polke, PhD11; Mary M. Reilly1; Nick W Wood, MD, PhD3; Emmanuele Crespan, PhD3; Christopher Gomez, MD, PhD12; Jin Yun Helen Chen, MSc13; Jeremy Dan Schmahmann, MD13; David Gosal, MD5; Henry Houlden, MD PhD6; Soma Das, PhD7; Andrea Cortese, MD, PhD1,2

Corresponding Author: Andrea Cortese, andrea.cortese@ucl.ac.uk

Affiliation Information for All Authors: 1. Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK; 2. Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 3. Institute of Molecular Genetics IGM-CNR "Luigi Luca Cavalli-Sforza", Pavia, Italy; 4. Department of Neurology, University Hospital Basel, University of Basel, Switzerland; 5. IRCCS Mondino Foundation, Pavia, Italy; 6. Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK; 7. Clinical Pharmacology, William Harvey Research Institute, School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK; 8. Departamento de Distúrbios do Movimento, Hospital Das Clínicas Da Universidade Federal Do Paraná, Curitiba, Brazil; 9. University of Chicago Medical Center, The University of Chicago, IL, USA; 10. Department of Human Genetics, The University of Chicago, Chicago, IL, USA; 11. Neurogenetics, University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK; 12. Department of Neurology, The University of Chicago, Chicago, IL, USA; 13. Ataxia Center, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Equal Author Contribution: These authors contributed equally to this work (co-first authors): Riccardo Ronco, Cecilia Perini, Riccardo Currò, Natalia Dominik. These authors contributed equally to this work (co-senior authors): Henry Houlden, Soma Das, Andrea Cortese.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes. Videos, if applicable, will be available when the article is published in its final form.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
ABSTRACT

Introduction
Cerebellar Ataxia, Neuropathy and Vestibular Areflexia Syndrome (CANVAS) is an autosomal recessive neurodegenerative disease characterized by adult onset and slowly progressive sensory neuropathy, cerebellar dysfunction, and vestibular impairment. In most cases, the disease is caused by biallelic (AAGGG)$_n$ repeat expansions in the second intron of the Replication Factor Complex subunit 1 (RFC1). However, a small number of cases with typical CANVAS do not carry the common biallelic repeat expansion. The objective of this study was to expands the genotypic spectrum of CANVAS by identifying point mutations in RFC1 coding region associated with this condition.

Methods
Fifteen individuals diagnosed with CANVAS and carrying only one heterozygous (AAGGG)$_n$ expansion in RFC1 underwent WGS or WES to test for the presence of a second variant in RFC1 or other unrelated gene. To assess the impact of truncating variants on RFC1 expression we tested the level of RFC1 transcript and protein on patients’ derived cell lines.

Results
We identified seven patients from five unrelated families with clinically defined CANVAS carrying a heterozygous (AAGGG)$_n$ expansion together with a second truncating variant in trans in RFC1, which included: c.1267C>T (p.Arg423Ter), c.1739_1740del (p.Lys580SerfsTer9), c.2191del (p.Gly731GlufsTer6) and c.2876del (p.Pro959GlnfsTer24). Patient fibroblasts containing the c.1267C>T (p.Arg423Ter) or c.2876del (p.Pro959GlnfsTer24) variants demonstrated nonsense-mediated mRNA decay and reduced RFC1 transcript and protein.
Discussion
Our report expands the genotype spectrum of RFC1 disease. Full RFC1 sequencing is recommended in cases affected by typical CANVAS and carrying monoallelic \((AAGGG)_n\) expansions. Also, it sheds further light on the pathogenesis of RFC1 CANVAS as it supports the existence of a loss of function mechanism underlying this complex neurodegenerative condition.

INTRODUCTION
Cerebellar Ataxia, Neuropathy and Vestibular Areflexia Syndrome (CANVAS) is an autosomal recessive neurodegenerative disease characterized by adult onset and slowly progressive ataxia caused by the contemporary impairment of sensory neurons, the vestibular system and the cerebellum\(^1\text{-}^3\). In most cases, the disease is caused by biallelic \((AAGGG)_n\) repeat expansion in the second intron of the Replication Factor Complex subunit 1 \((RFC1)\) gene\(^4\text{-}^{21}\). RFC1 encodes the large subunit of replication factor C, a 5-subunit DNA polymerase accessory protein required for the coordinated synthesis of both DNA strands during replication and after DNA damage.

Notably, previous studies in biallelic \((AAGGG)_n\) expansion carriers using patients’ cell lines and one post mortem brain did not show a reduction of RFC1 RNA or protein, nor an overt dysfunction of DNA replication and repair\(^4,^9\). This is puzzling, since recessively inherited conditions are typically associated with loss of function of the mutant gene, and suggests that more complex mechanisms may be involved in the pathogenesis of RFC1 CANVAS.

Here, we present the first seven cases from five unrelated families affected by the typical CANVAS phenotype carrying a heterozygous \((AAGGG)_n\) repeat expansion together with a second truncating variant in RFC1.

METHODS

Patients
DNA samples were collected from patients diagnosed with ataxia, sensory neuropathy or CANVAS at the National Hospital for Neurology and Neurosurgery at Queen Square Institute of Neurology (London, UK), at the University of Chicago Genetic Services Laboratory (Chicago, USA) and internationally through collaborating centers between January 2019 and January 2022. Patients were diagnosed as having CANVAS based on the characteristic combination of sensory neuronopathy, cerebellar dysfunction and bilateral vestibular areflexia\(^1\).

RFC1 testing
RFC1 genetic test was performed using repeat primed polymerase chain reaction (RP-PCR) and flanking PCR as previously described\(^4,^{21}\). When sufficient DNA was available Southern Blotting was also performed\(^4\).

Whole-genome sequencing (WGS) and Whole-exome sequencing (WES)
Individuals diagnosed with CANVAS and carrying only one heterozygous (AAGGG)\textsubscript{n} expansion in RFC1 underwent WGS or WES. WGS and WES were performed by Macrogen (Netherlands) or at the University of Chicago. At Macrogen, paired-end sequencing reads (150 bp) were generated using a Novaseq 6000 system (Illumina) and aligned to GRCh38 using the Burrows–Wheeler Aligner\textsuperscript{22}. The mean coverage per sample was 40x. Variants were called according to the GATK HaplotypeCaller workflow\textsuperscript{23} and annotated with Ensembl VEP\textsuperscript{24}. Variants were prioritized based on segregation, minor allele frequency (<0.0001 in the 1000 Genomes Project\textsuperscript{25}, National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project (ESP) (Exome Variant Server, NHLBI GO ESP, [http://evs.gs.washington.edu/EVS/], or the Genome Aggregation Database\textsuperscript{26}), evolutionary conservation, and in silico prediction of pathogenicity for coding variants. The process of WES at the University of Chicago was similar with the following exceptions: exome sequencing was performed using the IDT xGEN Exome Research kit (Integrated DNA Technologies) and sequence was aligned to GRCh37. Variants were annotated and evaluated using a validated, custom bioinformatic pipeline.

**RFC1 expression studies in patient derived cell lines**

To assess the impact of truncating variants on RFC1 expression, patients’ fibroblasts from affected (I-1, I-2) and unaffected (I-3) individuals from family 1, case II from family 2, patients carrying biallelic AAGGG expansion (n=5) and age and gender matched controls (n=5) were harvested and grown in culture in DMEM supplemented with 15% Fetal bovine serum (Euroclone). Real-Time Quantitative PCR (RT-qPCR) and Western Blotting were replicated on biologically independent samples at least twice with similar results.

**RFC1 gene silencing in HEK293 cell lines**

In order to validate anti-RFC1-p140 mouse monoclonal (1:2’500, kind gift of Ulrich Hubscher\textsuperscript{27}), we performed RFC1 gene silencing as described in\textsuperscript{28}. Briefly, HEK293 human neuroblastoma (ECACC) were cultured in a T75 flask and maintained in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (Thermo Fisher Scientific) at 37°C in a 5% CO\textsubscript{2} humidified incubator. HEK293 were splitted at \approx 80% confluence and replated in a 6-well plate (800.000 cells per well). To silence RFC1 25 pmol of siRNA pool (siRFC1: 5’-GUAAAUAGCUCCCGUAAG-3’; 5’-GGAAUUAAUUGGCCUGAUA -3’; 5’-GUCCAAAGAUCUAAUAAAGA-3’; 5’-CAUAUGCGAUGGUGACCUCUA-3’) or non-targeting siRNA (D-001810-10-05, Thermo Fisher scientific) were mixed with 7.5 µl of Lipofectamine RNAiMAX (Invitrogen) following manufacturer’s transfection protocol and applied to each well of a 6-well plate. 48 h later, transfected cells were collected for subsequent analysis.

**Real-Time Quantitative PCR (RT–qPCR)**

Total RNA was extracted from fibroblasts using RNAeasy Mini kit (Qiagen) and treated with RNase-free DNase I (Qiagen). Complementary DNA (cDNA) was synthesized using 500 ng total RNA for all samples, with a SuperScript III First Strand cDNA Synthesis Kit (Invitrogen) and an equimolar mixture of oligo (dT)18 and random hexamer primers. Real-time qRT–PCR was carried out using the Power SYBR Green Master Mix (Applied Biosystems) and measured with a QuantStudio 7 Flex Real-Time PCR System (Applied
**RFC1** expression level (Forward: 5'-CTTCGCGGAGAAGTTGTTG-3', Reverse: 5'-ATTTCGAATGTCACAATCGAG-3') was normalized to GAPDH (Forward = 5'-TGCACCACCAACTGTTAGC-3', Reverse = 5'-GGCATGGACTGTTGTCATGAG-3') and RPL10 (Forward = 5'-AATCTCCAGGGGACACCATT-3', Reverse = CGCTGGCTCCACCATTG-3'). Amplified transcripts were quantified using the comparative CT method and presented as normalized fold expression change ($2^{ΔΔCt}$). In order to assess the allelic status of the c.2876del (p.Pro959GlnfsTer24) truncating variant mapping to exon 22 in individual II, we took advantage of the presence of a c.2511T>C (p.Ser837=) (rs2066782) synonymous variant on exon 19 which is part of the same haplotype containing the (AAGGG)n repeat expansion. cDNA from patient’s fibroblasts was amplified by touchdown PCR encompassing exons 17-23 (Forward: 5'-TCTTCGTTCATCAAGACCTCGG-3', Reverse: 5'-TTTGCCACCCCAGCTGCTG-3') and Sanger sequencing was performed on exon 19 (Forward: 5'-GGTGAGCCCAATCAAGATATCGA-3' Reverse: 5'-GCTGCAAACACTTTCCGGG-3') and exon 22 (Forward: 5'-CTGGAGTCTTCTGCCTGCGC-3' Reverse: 5'-GGTCAGGGCTGTACAAGTGCA-3') using both forward and reverse primers. For comparison, PCR and sequencing of exon 19 (Forward: 5'-GGTGTCACAGAATGAAAGC-3' Reverse: 5'-ATCCACAGGCATACCAAG-3') and exon 22 (Forward: 5'-TGGATCAAGGTGTACCGC-3' Reverse: 5'-CCCGAACAGATGTAATCCCAC-3') of RFC1 were also performed on gDNA from case II.

**Western blotting**

Cells were collected in cold PBS 1X, resuspended in RIPA buffer [1% Nonidet P-40, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.1% DOC] supplemented with 1X protease inhibitor cocktail (Sigma Aldrich) and 1X phosphatase inhibitor cocktail (Roche Diagnostics), incubated for 20 minutes on ice, then centrifuged (15 min at 6’200 g, 4 °C) and the protein-containing supernatant was collected. Protein lysates concentrations were assessed using Protein Assay Dye Reagent Concentrate (Bio-Rad). Lysates (25 µg) were mixed with 1X cracking buffer [300mM Tris-HCl (pH 6.8), 10% SDS, 40% glycerol, 600 mM DTT, 5% 2-mercaptoethanol, 0.2% bromophenol-blue] and denatured for 5 minutes at 95°C. Samples were separated in 8% SDS-polyacrylamide gel in 1X Tris/Glycine/SDS running buffer and transferred onto nitrocellulose membrane using a Turbo Transfer Pack (Bio-Rad). Membranes were then blocked 1h in 6% skimmed milk and incubated over-night at 4°C with 2.5% skimmed milk with the following antibodies recognizing human proteins: anti-RFC1-p140 mouse monoclonal (1:2’500, kind gift of Ulrich Hubscher27), anti-GAPDH mouse monoclonal (cat. no. ab8245; 1:10000; Abcam) or anti α-Actinin (cat. No. 3134, Cell Signaling). Specificity of anti-RFC1-p140 was validated by assessing binding in siRFC1-HEK293 cell line. Primary antibodies were probed with horseradish peroxidase-conjugated secondary antibodies (anti-mouse, cat. no. 115-035-146; 1:5’000; Jackson ImmunoResearch Laboratories, Inc.) for 1h at room temperature. Protein bands were visualized using an enhanced chemiluminescent reagent (Westar Eta C Ultra 2.0; Cyanagen). The intensity of the band in each sample was quantified using QuantityOne software (Bio-Rad Laboratories, Inc.), corrected for the intensity of the corresponding band obtained with the anti-GAPDH antibody, and normalized to the control sample.
**RNA-seq**
Library preparation and RNAseq were performed at UCL genomics. Reads were aligned to the hg38 human genome build using STAR (version 2.7.7a)\(^29\). BAM files were sorted and duplicate reads flagged using umi_tools (version 1.1.1)\(^30\). The aligned reads overlapping the human genes (Gencode v35) were counted with featureCounts (version 2.0.1)\(^31\).

**Standard protocol approvals, registrations, and patient consents**
The study was approved by local institutional ethical committees. Written informed consent was obtained from patients, all aged over 18 years, participating in the study.

**Data availability**
Anonymized data from this study will be shared by request from any qualified investigator.

**RESULTS**

**RFC1 genetic studies**
As part of RFC1 genetic testing at the Queen Square Institute of Neurology and at the University of Chicago, we identified 15 subjects from 13 families with a clinical diagnosis of typical CANVAS who carried only one heterozygous \((AAGGG)\_n\) expanded allele. WES or WGS was performed and identified a second truncating variant in RFC1 in seven of them, from five unrelated families (5/13, 38%), who are further described here (Figure 1). No other relevant variant, including splicing or non-coding variants in RFC1 or other genes, was identified in the remaining seven families.

**Case description**

**Family 1**
I-2 was referred for neurologic evaluation for progressive imbalance, reduced sensation in her hands and feet and oscillopsia since her mid 50s. She has also complained of chronic cough since the age of 15.

Neurologic examination in I-2 at the age of 61 showed a broad-based gait and positive Romberg. There was gaze-evoked nystagmus, broken pursuits, absent vestibular ocular reflex bilaterally and altered visually enhanced vestibulo-ocular reflex (VVOR). Sensation to pinprick was reduced all over including the face, while sensation to vibration was reduced to the sternum in the upper limbs and to the anterior superior iliac spine in the lower limbs. Joint position was preserved. Reflexes were reduced in the upper and lower limbs. There was mild dysmetria to finger-nose and heel-shin. Tone, muscle bulk and power were normal (Video_1).

Nerve conductions studies showed absent sensory action potentials in the upper and lower limbs but normal motor studies. MRI showed vermal atrophy involving the ventral and dorsal lobules and cord parenchymal volume loss that involved the entire cord and
preferentially the dorsal aspect, wherein faint longitudinally extensive T2 hyperintensity was shown to involve the dorsal columns. Vestibular testing confirmed the presence of bilateral vestibular failure.

In her family, her older sister (I-1), now aged 62, also reported similar symptoms while their younger brother (I-3) and their parents were unaffected. I-1 describes the onset of a chronic cough from her early 20s. Since her late 40s she has been complaining of unsteadiness, worse in the dark, followed a few years later by neuropathic pain and oscillopsia related to head movements, with difficulty reading road signs when walking. The condition progressed and she developed dysarthria, swallowing difficulties, as well as autonomic involvement with symptomatic orthostatic hypotension. Examination and investigations at the age of 62 supported a clinical diagnosis of CANVAS. I-3 did not report any symptoms. He had normal examination and nerve conduction studies at the age of 52.

\textit{RFC1} testing in I-1 and I-2 showed the presence of heterozygous \((\text{AAGGG})_n\) expansion of 1000 repeats together with a non-expanded \((\text{AAAAG})_{11}\) allele. I-3 also carried the \((\text{AAGGG})_{1000}\) expansion in compound heterozygous state with a small non-pathogenic expansion of \((\text{AAGGG})_{60}\) repeats on the other allele. WGS was thus performed and showed in I-1 and I-2, but not in I-3, the presence of a c.1267C>T (p.Arg423Ter) truncating variant in \textit{RFC1} (NM_002913.5).

\textbf{Family 2}

Case II is a 64-year-old male who has been complaining since his late 40s of progressive imbalance, which was worse in the dark, associated with numbness, paresthesia, and diffuse neuropathic pain in his four limbs coupled with an intense cold pain sensation affecting his torso. Oscillopsia and symptoms suggestive of autonomic failure, including orthostatic hypotension with syncopal episodes, bladder, bowel, and sexual dysfunction, were also later reported. He was adopted and has never had any contact with his biological family. Examination at the age of 64 showed bilateral vestibular areflexia, together with signs of cerebellar dysfunction and sensory impairment. Brain MR imaging showed mild cerebellar atrophy. Nerve conduction studies revealed the presence of a severe sensory neuronopathy with absent sensory action potentials throughout but normal motor studies. Vestibular testing showed bilateral vestibular areflexia. \textit{RFC1} testing was performed and showed the presence of a heterozygous \((\text{AAGGG})_n\) repeat expansion in \textit{RFC1}. WES was performed and identified a second c.2876del (p.Pro959GlnfsTer24) truncating variant in \textit{RFC1}. Direct segregation of variants was not possible due to the lack of family members. However mRNA sequencing studies were performed and provided evidence that \((\text{AAGGG})_n\) repeat expansion and c.2876del (p.Pro959GlnfsTer24) variant reside on separate alleles (see paragraph \textit{RFC1} expression studies and Figure 2D).

\textbf{Family 3}

Case III is a 41 years-old female who reports progressive imbalance and walking difficulties, particularly in the darkness, since the age of 30. Notably, she has always felt clumsy and was unathletic in school. Chronic cough was reported since young age. Oscillopsia and impaired hand dexterity were also later noted, while dysarthria was evident since the age of 40. The disease progressed fairly rapidly, and she has been using a walking aid since the age of 38.
and a wheelchair since the age of 40. Examination at the age of 41 showed gaze evoked and downbeat nystagmus and saccadic pursuit. Vibratory sensation and proprioception were reduced in the toes while pinprick sensation was reduced to the knees in the lower limbs and the wrists in the upper limbs. Muscle tone and power were normal throughout while reflexes were increased in the four limbs.

Bilateral vestibular impairment was documented by the age of 30, while recent investigations showed the association of cerebellar atrophy and sensory neuronopathy. RFC1 testing was performed and showed the presence of a heterozygous (AAGGG)_n repeat expansion in RFC1. WES was performed and identified a second c.1739_1740del (p.Lys580SerfsTer9) truncating variant in RFC1. Parental testing was subsequently performed that determined the presence of the (AAGGG)_n repeat expansion in this individual’s mother and the c.1739_1740del (p.Lys580SerfsTer9) truncating variant in this individual’s father, confirming that the variant and the repeat expansion are in trans configuration.

**Family 4**
Case IV-1 reports distal sensory loss, itch and burning pain in his mid 40s, which progressed proximally to involve his trunk and face, and which were followed shortly after by imbalance, especially with eyes closed, falls, slurred speech, blurred vision in lateral gaze and orthostatic hypotension. A dry cough was reported since the age of 20. Examination at the age of 47 showed normal gait but difficulties at tandem walking. There were gaze evoked nystagmus, saccadic pursuit, abnormal VVOR and mild dysarthria. Reflexes were brisk but the motor compartment was otherwise intact. Sensation to pinprick was reduced in the limbs and trunk, vibration was reduced to the knees while proprioception was normal. Investigations were in keeping with full blown CANVAS documenting the presence of vestibular areflexia, sensory neuropathy and cerebellar atrophy. RFC1 testing was performed and showed the presence of a heterozygous (AAGGG)_n repeat expansion in RFC1. WES was performed and identified a second c.2191del (p.Gly731GlufsTer6) truncating variant in RFC1. This individual was described to have an older sibling (IV-2) of 54 years diagnosed with ataxia. He is currently wheelchair-bound and requires feeding tube due to severe dysphagia. RFC1 analysis in this older sibling identified the presence of the (AAGGG)_n repeat expansion and the c.2191del (p.Gly731GlufsTer6) truncating variant. Parental analysis determined the presence of the c.2191del (p.Gly731GlufsTer6) variant in the father and the (AAGGG)_n repeat expansion in the mother, confirming that the variant and the repeat expansion are in trans configuration.

**Family 5**
Case V reported onset of imbalance at the age of 26, particularly at night, which progressed over the years and was associated with chronic cough and mild dysarthria. Examination at the age of 33 showed a broad-based gait and positive Romberg. There was downbeat nystagmus, exaggerated by lateral gaze, saccadic pursuit and positive head impulse test. Reflexes were brisk and, notably, tone was increased in the lower limbs with sustained ankle clonus. However, power was normal and Babinski negative. Superficial sensation was reduced with distal-to-proximal gradient and proprioception was reduced at the toes. There was mild finger-nose and heel-shin ataxia.
Investigations showed the presence of a pure sensory neuropathy with normal motor nerve conduction studies, along with moderate diffuse cerebellar and vermillion volume loss at brain MRI and abnormal vestibular testing.

RFC1 testing was performed and showed the presence of a heterozygous (AAGGG)_n repeat expansion in RFC1. WES was performed and identified a second c.1267C>T (p.Arg423Ter) truncating variant in RFC1. This variant is the same as that detected in family 1. Analysis of this individual’s father demonstrated that he carries the c.1267C>T (p.Arg423Ter) truncating variant and does not carry the (AAGGG)_n repeat expansion. The mother of this individual was not available for analysis. This result supports that the variant and the repeat expansion are in trans configuration.

**RFC1 expression studies**

To determine whether the observed truncating variants would lead to nonsense-mediated mRNA decay and haploinsufficiency of RFC1 we evaluated both the RNA and protein expression of the gene (Figure 2A-D). RT-qPCR was performed on RNA extracted from the fibroblasts of affected I-1, I-2 and II individuals and showed a reduced level of RFC1 mRNA compared to their unaffected sibling I-3, biallelic AAGGG expansion carriers and controls. (Figure 2A). RNAseq from I-1 and I-2 confirmed the presence of a ~50% decrease in RFC1 transcript level (Figure 2B). Notably the reduced expression was due to the lower number of reads containing the c.1267C>T variant, which accounted for less than 10% of the total number of reads in the region, as opposed to an equal representation of the two alleles on WGS (Figure 2C). Touchdown PCR followed by Sanger sequencing also showed nonsense mediate decay of the allele containing the c.2876del truncating variant in case II. Notably, the (p.Ser837=) (rs2066782) synonymous variant which is part of the haplotype containing the (AAGGG)_n expansion was shown as heterozygous on gDNA from the patient but as “homozygous” on cDNA suggesting that the c.2876del variant and (AAGGG)_n expansion reside on separate alleles (Figure 2D). Together, the findings suggest that the transcript containing truncating variants in RFC1 undergo nonsense-mediated decay leading to RNA degradation. Accordingly, immunoblotting showed a concordant reduction of the 140KD full length RFC1 protein in fibroblasts from affected individuals, as well as in siRFC1 HEK293 cell line, compared to biallelic AAGGG expansion carriers and controls, while no truncated isoforms were detected (Figure 2E).

**DISCUSSION**

The study reports the first cases of RFC1 CANVAS associated with truncating variants in the RFC1 gene. Although the molecular consequence of biallelic repeat expansions in RFC1 remains unsolved, the observation of patients carrying compound heterozygous truncating variant/(AAGGG)_n repeat expansion in RFC1, resulting in reduction of RFC1 expression, has major implications on future studies on the disease pathogenesis as it supports the existence of a loss of function mechanism underlying this condition. Efficient repair of oxidative DNA damage is an essential function for neurons as they do not replicate and have limited protein turnover. Therefore, even a subtle impairment of the replication factor complex machinery may be detrimental to this cell type. Indeed, complete loss of RFC1 is not compatible with life in cellular and animal models and the gene is highly
intolerant to haploinsufficiency based on control database data. Further investigations in disease-relevant tissues are warranted to test this hypothesis.

Patients carrying a completely nonfunctional allele together with a second heterozygous (AAGGG)$_n$ expanded allele seemed to show a relatively severe phenotype with dysautonomia, as well as an earlier need for walking aids compared to most patients carrying biallelic (AAGGG)$_n$ repeat expansions (Table 1). Notably, two cases (III, IV-2) were wheelchair bound by the age of 50 and one case (IV-2) required tube feeding due to severe dysphagia. Individual V had the earliest onset of the disease, in her mid 20s, and a severe phenotype with clinical involvement of upper motor neurons leading to an increased tone. Brisk reflexes are common in RFC1 disease, however additional motor features and pyramidal signs are more rarely identified. The observation of a spastic-ataxic syndrome in case V confirms the possibility of clinically manifest upper motor neuron involvement in severe RFC1 disease.

Arguably, the identification of truncating variants in RFC1 leading to a relatively severe phenotype also supports a loss of function model of RFC1 disease, where no or very low production of RFC1 protein from one allele has more severe functional and clinical consequences compared to biallelic expansions. It is possible that the severity of the disease and clinical phenotype in patients carrying one truncating variant was influenced by the expansion size on the second allele. Unfortunately, there was not enough DNA from most cases to perform Southern Blotting and test this hypothesis.

Other recessively inherited conditions have previously been associated with compound heterozygous pathogenic variants/repeat expansion genotypes. For example, approximately 1-4% of individuals with Friedreich ataxia have an abnormally expanded GAA repeat in the disease-causing range on one frataxin (FXN) allele and another intragenic pathogenic variant on the other allele. More recently noncoding GCA and GCC repeat expansion in compound heterozygous state with a second missense or truncating variant were identified as causative of two other rare inherited conditions, glutaminase deficiency and Baratela-Scott syndrome respectively, leading to a clinical phenotype indistinguishable from patients with biallelic pathogenic variants. Of note, loss of function of the repeat containing genes has been established for all these conditions.

RFC1 appears intolerant to loss of function as demonstrated by the presence of only 11 RFC1 truncating variants out of 251,000 alleles present on gnomAD v2.1.1 (allele frequency= 0.00002) with an observed/expected ratio lower than 0.35 (o/e=0.18, 90% CI = 0.12-0.3) and a very high probability of being Loss-of-Function intolerant (pLI = 0.97). Furthermore, there are only 18 RFC1 truncating variants out of 150,000 alleles from individuals enrolled in the Genomics England WGS sequencing project, without (AAGGG)$_n$ expansion on the second allele. Biallelic truncating variants are absent from public control databases or Genomics England WGS as they would not be compatible with life. Nonetheless, parents of the affected patients in the present study, carrying a truncating variant in RFC1 but no AAGGG expansion on the second allele, did not show a phenotype despite their old age, suggesting that haploinsufficiency of RFC1, albeit rare in the general population, is tolerated. In fact, a pathogenic mechanism due to hemizygous expression of the repeat containing allele, which is not sufficient to cause disease when coexpressed with normal protein, cannot be excluded. In this scenario, it could be hypothesized that the only available transcript originating from the repeat containing allele may exert a similar
detrimental effect to biallelic expansions, possibly through gain of function of toxic RNA or repeat peptides.

It should be noted that the c.1267C>T (p.Arg423Ter) variant that was detected in two independent families in our cohort is present in the gnomAD population database in two individuals, one of East Asian and one of European (non-Finnish) ancestry. The c.1267C>T change does occur at a CG dinucleotide which may explain its susceptibility to being mutated and it may represent a more common pathogenic variant in CANVAS.

In seven families with typical CANVAS and one expanded (AAGGG) allele a definite cause was not identified, suggesting the possible presence of genetic heterogeneity underlying CANVAS phenotype.

Our report expands the genotype spectrum of RFC1 disease and has direct diagnostic implications. Indeed, albeit rare in our cohort (seven cases vs over 650 individuals carrying biallelic RFC1 expansions, ~1%), the finding of truncating variants associated with CANVAS indicate that full RFC1 sequencing is recommended in cases affected by typical CANVAS and carrying monoallelic (AAGGG)_n expansions.

**TABLES**

**Table 1. Comparison of patients with truncating variants in RFC1 and biallelic (AAGGG)_n patients**

<table>
<thead>
<tr>
<th>Case</th>
<th>I-1 (family 1)</th>
<th>I-2 (family 2)</th>
<th>II (family 3)</th>
<th>III (family 4)</th>
<th>IV (family 4)</th>
<th>IV-2 (family 5)</th>
<th>V (family 5)</th>
<th>Compound truncating variant/ (AAGGG)_n expansion</th>
<th>Biallelic (AAGGG)_n patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFC1 genotype</td>
<td>c.1267C&gt;T (p.Arg423Ter)/ (AAGGG)_n expansion</td>
<td>c.1267C&gt;T (p.Arg423Ter)/ (AAGGG)_n expansion</td>
<td>c.2876del (p.Pro959GlnfsTer24)/ (AAGGG)_n expansion</td>
<td>c.1739_1740del (p.Lys580SerfsTer9)/ (AAGGG)_n expansion</td>
<td>c.2191del (p.Gly731GlufsTer6)/ (AAGGG)_n expansion</td>
<td>c.1267C&gt;T (p.Arg423Ter)/ (AAGGG)_n expansion</td>
<td>c.1267C&gt;T (p.Arg423Ter)/ (AAGGG)_n expansion</td>
<td>truncate variant/ (AAGGG)_n expansion</td>
<td>(AAGGG)_n expansion/ (AAGGG)_n expansion</td>
</tr>
<tr>
<td>Provenance</td>
<td>London (UK)</td>
<td>London (UK)</td>
<td>Manchester (UK)</td>
<td>Chicago (USA)</td>
<td>Boston (USA)</td>
<td>Boston (USA)</td>
<td>Boston (USA)</td>
<td>UK and USA</td>
<td>UK, Europe, North and South America, Australia, New Zealand</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Caucasian</td>
<td>Caucasian</td>
<td>Caucasian</td>
<td>Caucasian</td>
<td>Caucasian</td>
<td>Caucasian</td>
<td>Caucasian</td>
<td>Caucasian</td>
<td>100% caucasian</td>
</tr>
<tr>
<td>Current age</td>
<td>62</td>
<td>61</td>
<td>64</td>
<td>43</td>
<td>47</td>
<td>54</td>
<td>33</td>
<td>54 (33-64)</td>
<td>63 (range 33–82)</td>
</tr>
<tr>
<td>Age of onset of imbalance (years)</td>
<td>45</td>
<td>55</td>
<td>47</td>
<td>30</td>
<td>45</td>
<td>40s</td>
<td>26</td>
<td>45 (26-55)</td>
<td>55 (30-80)</td>
</tr>
<tr>
<td>Age at use of walking aids (years)</td>
<td>58</td>
<td>59</td>
<td>59</td>
<td>38; wheelchair since age 40</td>
<td>not needed</td>
<td>Wheel-chair bound by the age of 50</td>
<td>Not needed</td>
<td>59 (38-59)</td>
<td>67 (37-83)</td>
</tr>
<tr>
<td>Clinical syndrome</td>
<td>CANVAS</td>
<td>CANVAS</td>
<td>CANVAS</td>
<td>CANVAS</td>
<td>CANVAS</td>
<td>CANVAS</td>
<td>CANVAS</td>
<td>100% CANVAS</td>
<td>63% CANVAS</td>
</tr>
<tr>
<td>Cough</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>100%</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Additional features</td>
<td>Orthostatic hypotension</td>
<td>Orthostatic hypotension</td>
<td>Orthostatic hypotension, bladder, bowel and sexual dysfunction</td>
<td>Corneal ulcers</td>
<td>Orthostatic hypotension</td>
<td>Severe Dysphagia requiring tube feeding</td>
<td>Increased tone</td>
<td>4/7 (57%) Orthostatic hypotension 2/7 (29%) wheelchair bound by the age of 50 1 case requiring tube feeding 1 case with spasticity</td>
<td>17% orthostatic hypotension 2% wheelchair bound by age 50 1 tube fed 0 spasticity</td>
</tr>
</tbody>
</table>

In the last 2 columns values are expressed as median value and range or %.

**FIGURE LEGEND**

Figure 1 Truncating variants in *RFC1* in compound state with pathogenic (AAGGG)$_n$ expansions cause CANVAS. A. Family pedigrees. B. Schematic diagram showing the location of mutations identified in this study on *RFC1* gene (NM_002913.5).
Figure 2. Nonsense-mediated mRNA decay and haploinsufficiency of RFC1. A. Real-Time qPCR showed a 40% reduction of RFC1 mRNA in two CANVAS cases carrying c.1267C>T/(AAGGG)exp (n=2) or c.2876del/(AAGGG)exp (n=1) mutations compared to healthy controls (n = 4, p value = 0.0305) and to biallelic (AAGGG)exp/(AAGGG)exp CANVAS cases (n = 4, p value < 0.0001). No significant reduction was seen in control vs biallelic CANVAS cases (p value = 0.154) B. RNAseq confirmed a significant reduction in RFC1 transcript level in patients I-1 and I-2 compared to healthy controls (n = 6, p value = 0.0086). C. Binary Alignment Maps (BAM) data from RNAseq and WGS performed in individuals from family 1 showed in I-1 and I-2 a lower number of reads containing the c.1267C>T mutation (green) compared reads mapping to the transcript derived from the second (brown), as opposed to an equal representation of the two alleles on WGS, supporting the presence of Non-sense Mediated Decay (NMD) of the c.1267C>T mutant transcript. Schematic representation of the percentage of cytosine and thymine called at c.1267 of RFC1 in WGS and RNAseq for family 1. D. Case II RFC1 gDNA and mRNA sequencing. The top left electropherogram show the presence on gDNA of the c.2876del frameshift variant, which is not evident on mRNA sequencing (bottom left) due to nonsense mediated decay. Conversely, the cytosine allele at base 2511, which is heterozygously expressed in gDNA and is part of the (AAGGG)n
expansion containing haplotype, appears as “homozygous” in the mRNA sequencing, due to nonsense-mediated decay of the second allele which contains the c.2876del truncating variant. Together the finding support the location in trans of (AAGG)n repeat expansion and c.2876del variant in this case.

E. Western Blotting revealed a 50% reduction of full length RFC1 protein expression (red arrow) in CANVAS patients (I-1 and I-2) vs healthy control (Control) and their unaffected sibling (I-3) (p value = 0.0263) along with a reduction of RFC1 in HEK293 cells upon siRFC1 transfection. Non targeting siRNA-transfected cells were used as a control. RFC1 densitometric values were normalized to GAPDH. No significant reduction in RFC1 protein expression was seen between biallelic (AAGGG)exp/(AAGGG)exp CANVAS patient-derived fibroblasts (n=5) and healthy control-derived fibroblasts (n=5) (p value = 0.94).
WNL-2022-201348_vid1 --- http://links.lww.com/WNL/C452
REFERENCES


15. Sullivan R, Yau WY, Chelban V, et al. RFC1-related ataxia is a mimic of early multiple system atrophy. *J Neurol Neurosurg Psychiatry*. Published online February 9, 2021.


Truncating Variants in RFC1 in Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome

Riccardo Ronco, Cecilia Perini, Riccardo Currò, et al.

Neurology published online October 26, 2022
DOI 10.1212/WNL.0000000000201486

This information is current as of October 26, 2022